drugset
drugset / Trial / NCT01738074

Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine

NCT01738074 ↗

Phase 3 Unknown 10020 enrolled Center for Disease Control and Prevention, Henan Province
RandomizedSingle-groupTriple-blindPrevention

Summary

Assessment and evaluation the rotavirus gastroenteritis prevention effect and severe rotavirus diarrhea reducing effectiveness of human body, which inoculate trivalent rotavirus genetic reassortment vaccine.

Timeline

Start
2012-08
Primary completion
2014-06
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject trivalent rotavirus genetic reassortment vaccine Vaccine 2 ml Oral

Indications

No indication recorded.